Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | TOP1 | P11387 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 8/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.33 |
| ▸ | KIT | P10721 | 6/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 3/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2199218 | 1.00 | LRRK2 (0.36) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2196779 | 0.87 | MAPK1 (0.37) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2196773 | 0.87 | MAPK1 (0.37) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2203048 | 0.86 | SCN10A (0.35) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2203053 | 0.86 | SCN10A (0.35) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2202400 | 0.84 | LRRK2 (0.37) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2202402 | 0.84 | LRRK2 (0.37) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2199234 | 0.83 | TOP1 (0.34) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2199233 | 0.83 | TOP1 (0.34) | LRRK2TOP1KDRMEN1KMT2A | |
| SCHEMBL2200634 | 0.82 | ROCK2 (0.38) | LRRK2TOP1KDRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455535-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | ALLERGAN, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977351-B2 | Heteroaryl dihydroindolones as kinase inhibitors | ALLERGAN, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2007109596-A2 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | ALLERGAN, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257238-A1 | Heteroaryl Dihydroindolones as Kinase Inhibitors | REN, JAK2, ABL1 | LRRK2 339/4885TOP1 2633/4885KDR 25/4885 |
| US-20080045526-A1 | HETEROARYL DIHYDROINDOLONES AS KINASE INHIBITORS | REN, JAK2, ABL1 | LRRK2 339/4885TOP1 2633/4885KDR 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.